Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company’s clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor ... Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company’s clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes. It has license agreements with National Cancer Institute for the clinical development of tuspetinib; and Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 12 | 0 | 0 | 4.44 | 4.44 | 4.44 | 0 | 0 | DE |
| 26 | 0 | 0 | 4.44 | 4.44 | 4.44 | 0 | 4.44 | DE |
| 52 | 0 | 0 | 4.44 | 4.44 | 4.44 | 0 | 4.44 | DE |
| 156 | 0 | 0 | 4.44 | 1998 | 4.44 | 24 | 78.53779853 | DE |
| 260 | 0 | 0 | 4.44 | 1998 | 4.44 | 123 | 12.78733772 | DE |
KRISGO
2分前
PickStocks
5分前
KRISGO
7分前
jour_trader
8分前
Augster
12分前
gfp927z
16分前
HenryB3
17分前
YB10
22分前
SmallCapStockAlert
22分前
Investor082
22分前
TexasMarvL
23分前
Large Green
25分前
Zadie420
29分前
BIOChecker4
29分前
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。